Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin

Pain

Volumn 141, Issue 1-2, 2009, Pages 60-69

  Gazerani, Parisa ^a,b   Pedersen, Natalia Spicina ^c   Staahl, Camilla ^a,c   Drewes, Asbjørn Mohr ^a,c   Arendt Nielsen, Lars ^a  

^a AALBORG UNIVERSITY   (Denmark)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Botulinum toxin; Capsaicin; Experimental pain

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; ISOTONIC SOLUTION; NEUROTRANSMITTER; PLACEBO; SODIUM CHLORIDE; VANILLOID RECEPTOR 1;

ARTICLE; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOREHEAD; HUMAN; HYPERALGESIA; MALE; NEUROGENIC INFLAMMATION; NEUROTRANSMITTER RELEASE; NORMAL HUMAN; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PRIORITY JOURNAL; SKIN PAIN; SKIN TEMPERATURE; TRIGEMINAL NERVE DISEASE; TRIGEMINAL PAIN; VASOMOTOR REFLEX;

ADULT; ANALYSIS OF VARIANCE; BOTULINUM TOXIN TYPE A; CAPSAICIN; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, INTRADERMAL; LASER-DOPPLER FLOWMETRY; MALE; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PAIN THRESHOLD; SKIN; SKIN TEMPERATURE; TRIGEMINAL NEURALGIA; VASOCONSTRICTION; YOUNG ADULT;

EID: 58149157911     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.10.005     Document Type: Article

References (59)

1. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43 (2003) S9-S15
2. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26 (2005) 785-793
3. Apostolidis A., Popat R., Yiangou Y., Cockayne D., Ford A.P., Davis J.B., et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174 (2005) 977-982
4. Arezzo J.C. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 18 (2002) S125-S132
5. Argoff C.E. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 18 (2002) S177-S181
6. Ateş Y. Botulinum toxin for the treatment of headaches: a review of current practices and evidence based-data. Agri 18 (2006) 5-11
7. Bach-Rojecky L., and Lacković Z. Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J 46 (2005) 201-208
8. Bach-Rojecky L., Relja M., and Lackovic Z. Botulinum toxine type A in experimental neuropathic pain. J Neural Transm 112 (2005) 215-219
9. Bartlett M.S. The use of transformations. Biometrics 3 (1947) 39-52
10. Blersch W., Schulte-Mattler W.J., Przywara S., May A., Bigalke H., and Wohlfarth K. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205 (2002) 59-63
11. Braune C., Erbguth F., and Birklein F. Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry. Br J Dermatol 144 (2001) 111-117
12. Brin M.F., Fahn S., Moskowitz C., Friedman A., Shale H.M., Greene P.E., et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2 (1987) 237-254
13. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288 (2000) 306-313
14. Caterina M.J. Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol 292 (2007) R64-76
15. Cruccu G., Anand P., Attal N., Garcia-Larrea L., Haanpää M., Jørum E., et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 11 (2004) 153-162
16. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 (2004) 125-133
17. Cui M., Li S., You S., Khanijou S., and Aoki K.R. Mechanisms of the antinociceptive effect of subcutaneous Botox inhibition of peripheral and central nociceptive processing (abstract). Naunyn Schmiedebergs Arch Pharmacol 365 (2002) R17
18. Dolly J.O., and Aoki K.R. The structure and mode of action of different botulinum toxins. Eur J Neurol 13 (2006) 1-9
19. Evers S., Vollmer-Haase J., Schwaag S., Rahmann A., Husstedt I.W., and Frese A. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24 (2004) 443-838
20. Fujisawa M., Shoji S., Ishibashi K., and Clark G.T. Pressure pain threshold with and without iontophoretic anesthesia of the masseter muscle in asymptomatic males. J Orofac Pain 13 (1999) 97-103
21. Gazerani P., Staahl C., Drewes A.M., and Arendt-Nielsen L. The effects of Botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122 (2006) 315-325
22. Greenspan J.D., and McGillis S.L. Stimulus features relevant to the perception of sharpness and mechanically evoked cutaneous pain. Somatosens Mot Res 8 (1991) 137-147
23. Humeau Y., Doussau F., Grant N.J., and Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82 (2000) 427-446
24. Ishikawa H., Mitsui Y., Yoshitomi T., Mashimo K., Aoki S., Mukuno K., et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44 (2000) 106-109
25. Jankovic J., and Schwartz K.S. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg [Am] 18 (1993) 883-887
26. Jensen K., Andersen H.O., Olesen J., and Lindblom U. Pressure pain threshold in human temporal region. Evaluation of a new pressure algometer. Pain 25 (1986) 313-323
27. Klein A.W., and Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg 24 (1998) 1184-1186
28. Koltzenburg M., Lundberg L.E., and Torebjork H.E. Dynamic and static components of mechanical hyperalgesia in human hairy skin. Pain 51 (1992) 207-219
29. Kosek E., Ekholm J., and Hansson P. Pressure pain thresholds in different tissues in one body region. The influence of skin sensitivity in pressure algometry. Scand J Rehabil Med 31 (1999) 89-93
30. Krämer H.H., Angerer C., Erbguth F., Schmelz M., and Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 250 (2003) 188-193
31. LaMotte R.H., Lundberg L.E., and Torebjork H.E. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol 448 (1992) 749-764
32. LaMotte R.H., Shain C.N., Simone D.A., and Tsai E.F. Neurogenic hyperalgesia psychophysical studies of underlying mechanisms. J Neurophysiol 66 (1991) 190-211
33. Luvisetto S., Marinelli S., Cobianchi S., and Pavone F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 145 (2007) 1-4
34. Mancini F., Zangaglia R., Cristina S., Sommaruga M.G., Martignoni E., and Nappi G.C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18 (2003) 685-688
35. Mathew N.T., Frishberg B.M., Gawel M., Dimitrova R., Gibson J., and Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45 (2005) 293-307
36. McMahon H.T., Foran P., Dolly J.O., Verhage M., Wiegant V.M., and Nicholls D.G. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid aspartate and met-enkephalin release from synaptosomes Clues to the locus of action. J Biol Chem 267 (1992) 21338-21343
37. Morenilla-Palao C., Planells-Cases R., García-Sanz N., and Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279 (2004) 25665-25672
38. Oguma K., Fujinaga Y., and Inoue K. Structure and function of Clostridium botulinum toxins. Microbiol Immunol 39 (1995) 161-168
39. Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18 (2003) 685-688
40. Park H.J., Lee Y., Lee J., Park C., and Moon D.E. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth 53 (2006) 470-477
41. Pearce L.B., First E.R., MacCallum R.D., and Gupta A. Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon 35 (1997) 1373-1412
42. Purkiss J., Welch M., Doward S., and Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59 (2000) 1403-1406
43. Purkiss J.R., Welch M.J., Doward S., and Foster K.A. Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms. Biochem Soc Trans 25 (1997) 542S
44. Reid K.I., Carlson C., Rayens M.K., and Gracely R.H. The influence of cutaneous tissue afferents on masticatory pain-pressure thresholds. J Orofac Pain 10 (1996) 324-329
45. Saper J.R., Mathew N.T., Loder E.W., DeGryse R., and VanDenburgh A.M. A double-blind randomised placebo-controlled exploratory study comparing injection sites with low doses of botulinum toxin type A in the prevention of episodic migraine. J Neurol 252 (2005) II-58
46. Schnider P., Binder M., Auff E., Kittler H., Berger T., and Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 136 (1997) 548-552
47. Schulte-Mattler W.J., and Leinisch E. Evidence based medicine on the use of botulinum toxin for headache disorders. J Neural Transm 115 (2008) 647-651
48. Schulte-Mattler W.J., Opatz O., Blersch W., May A., Bigalke H., and Wohlfahrt K. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin. J Neurol Sci 260 (2007) 38-42
49. Serra J., Campero M., and Ochoa J. Flare and hyperalgesia after intradermal capsaicin injection in human skin. J Neurophysiol 80 (1998) 2801-2810
50. Silberstein S.D., Göbel H., Jensen R., Elkind A.H., DeGryse R., Walcott J.M., et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 26 (2006) 790-800
51. Silberstein S.D., Stark S.R., Lucas S.M., Christie S.N., Degryse R.E., and Turkel C.C. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80 (2005) 1126-1137
52. Swartling C., Färnstrand C., Abt G., Stålberg E., and Naver H. Side-effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study. Eur J Neurol 8 (2001) 451-456
53. Sycha T., Samal D., Chizh B., Lehr S., Gustorff B., Schnider P., et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 102 (2006) 509-516
54. Takahashi K., Taguchi T., Itoh K., Okada K., Kawakita K., and Mizumura K. Influence of surface anesthesia on the pressure pain threshold measured with different-sized probes. Somatosens Mot Res 22 (2005) 299-305
55. Tsui J.K., Eisen A., Stoessl A.J., Calne S., and Calne D.B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2 (1986) 245-247
56. Tugnoli V., Capone J.G., Eleopra R., Quatrale R., Sensi M., Gastaldo E., et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 130 (2007) 76-83
57. Voller B., Sycha T., Gustorff B., Schmetterer L., Lehr S., Eichler H.G., et al. A randomized, double-blind, placebo-controlled study on analgesic effects of botulinum toxin A. Neurology 61 (2003) 940-944
58. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 (2000) 245-258
59. Yarnitsky D., Sprecher E., Zaslansky R., and Hemli J.A. Heat pain thresholds: normative data and repeatability. Pain 60 (1995) 329-332